AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jun 15, 2018
33422_dirs_2018-06-14_73db5095-60c3-4da4-ac55-f40acb16dc82.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-13
Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-13 | Common Stock | S | 60000 | $6.59 | Disposed | 2949786 | Indirect |
| 2018-06-13 | Common Stock | S | 60000 | $7.09 | Disposed | 2889786 | Indirect |
| 2018-06-13 | Common Stock | S | 60000 | $7.47 | Disposed | 2829786 | Indirect |
| 2018-06-13 | Common Stock | S | 28140 | $7.97 | Disposed | 2801646 | Indirect |
Footnotes
F1: Common shares should pursuant to a trading plan pursuant to Rule 10b5-1. Price represents the gross sales price less commissions and brokerage fees.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.